EZZ Life Science Holdings

US Rebranding And New Product Launches Will Broaden Global Reach

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

24 Apr 25

Updated

01 May 25

n/a

AnalystConsensusTarget's Fair Value

n/a

-41.3%

-16.7%

-41.3%

-16.7%

You can edit this narrative until May 12 6:00 AM. Then, changes will post as Updates.

Author's Valuation

AU$569.0% undervalued

AnalystConsensusTarget Fair Value

Narrative

Updates1

Shared on 01 May 25

AnalystConsensusTarget Fair Value

AU$5

69.0% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

21.45%

Personal Products revenue growth rate

0.15%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

7.19%

Calculation

AU$14.29m

Earnings '28

20.04x

PE Ratio '28

AU$286.35m

Market Cap '28

AU$286.35m

Market Cap '28

47.17m

No. shares '28

AU$6.07

Share Price '28

AU$6.07 Share Price '28

Discounted to 2025 @ 6.81% p.a.

AU$4.98

Fair Value '25